HOME >> BIOLOGY >> NEWS
Potential blood test for colon cancer risk

Johns Hopkins scientists have found a way to predict with a simple blood test which people may be at higher than normal risk for the most common form of colon cancer. The research, described in the March 14, 2003 issue of Science, focuses on genetic "red flags" housed not in the sequence of the DNA building blocks themselves, but in other subtle modifications made to the genetic code.

"We hope these findings will have the ability to identify people at increased risk for colon cancer, follow them closely and prevent disease or at least catch it early, similar to the approach doctors use in identifying patients at risk of heart disease," says Andrew P. Feinberg, M.D., King Fahd Professor of Medicine in the Kimmel Cancer Center at Johns Hopkins.

At present, the genetic marker blood tests are for research purposes only, Feinberg emphasized. "More efficient tests will take several more years at least to develop," said Feinberg, who with Hengmi Cui, Ph.D., and Marcia Cruz-Correa, M.D., Ph.D., led the study. "We also need to follow patients over time to see if they develop cancer after the test is positive," he added.

Prior research at Hopkins and elsewhere has identified genetic mutations linked specifically to hereditary forms of colon cancer. The genetic information uncovered in this study applies to the much more common forms of colon cancer that occur sporadically among the general population. An estimated 155,000 cases are diagnosed annually in the United States.

Earlier work also by the Feinberg team has shown that a form of gene silencing called loss of imprinting (LOI) in a growth-promoting gene called IGF2 (for insulin like growth factor) is one of the first genetic defects that happen in up to 40 percent of colon cancers. In the new study, the researchers found IGF2-related LOI present in blood samples as well as in colon tissue.

In an analysis of blood samples from 172 individuals who had a colonoscopy, a t
'"/>

Contact: Vanessa Wasta
wastava@jhmi.edu
410-955-1287
Johns Hopkins Medical Institutions
13-Mar-2003


Page: 1 2 3

Related biology news :

1. Potential for enhanced sequestration of carbon in soils supports evaluations
2. Potential new treatment for Gaucher disease developed by scientists at Scripps Research Institute
3. Potential cause of arthritis discovered
4. Potential of regenerative medicine explored
5. Potential therapy reported for children, adults with end-stage liver disease
6. Potential allergy vaccine boosts hope for sufferers
7. Potential of tailoring drugs to genetic makeup confirmed--but challenges remain
8. Potential new anthrax therapy discovered
9. Potential gene therapy carriers created that mimic viruses, without the risk
10. New Class Of Synthetic Capsules That Mimic Biological Cells Has Wide Array Of Potential Uses
11. Role Of Protein Linked To Colon Cancer Identified, Offering Potential Target For Therapy

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... by 2021 from $8.3 billion in 2016 at a ... to 2021. Report Includes - An overview of ... market trends, with data from 2015 and 2016, and ... - Segmentation of the market on the basis of ...
(Date:2/7/2017)... Feb. 7, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, will present at the LEERINK Partners 6th Annual ... Hotel on Wednesday, February 15, 2017 at 10 a.m. ... the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
(Date:2/6/2017)... , Feb. 6, 2017 According to ... are driving border authorities to continue to embrace ... there are 2143 Automated Border Control (ABC) eGates ... deployed at more than 163 ports of entry ... to 2016 achieving a combined CAGR of 37%. ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... ... February 24, 2017 , ... Delpor, Inc. (Delpor), a biotechnology company focused ... Institute of Mental Health (NIMH) for the further advancement of the company’s 3-month olanzapine ... and is expected to deliver therapeutic levels of olanzapine for a period of 3 ...
(Date:2/24/2017)... , Feb. 24, 2017 Symic Bio, a ... a new category of therapeutics, announced today the completion ... in peripheral artery disease. The trial will evaluate the ... therapeutic, in the reduction of restenosis following angioplasty. ... development milestone for SB-030," said Nathan Bachtell , ...
(Date:2/24/2017)... 23, 2017 China Biologic Products, Inc. (NASDAQ: CBPO) ... biopharmaceutical company in China, today announced its financial results for ... Fourth Quarter 2016 Financial Highlights ... 21.7% in RMB terms, or increased by 13.6% in USD ... quarter of 2015. Gross profit increased by ...
(Date:2/23/2017)... 23, 2017 ... per share data, unaudited)Three Months Ended December 31,Twelve Months ... $         ...   89026%Aldurazyme Net Product Revenue ... Net Product Revenue  756025%297303(2)%Vimizim Net ...
Breaking Biology Technology:
Cached News: